Topics

Companies Related to "Scotland provide year cystic fibrosis drug" [Most Relevant Company Matches] RSS

11:55 EDT 21st October 2019 | BioPortfolio

Here are the most relevant search results for "Scotland provide year cystic fibrosis drug" found in our extensive corporate database of over 50,000 company records.

Showing "Scotland provide year cystic fibrosis drug" Companies 1–25 of 8,800+

Extremely Relevant

Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Instit...


Cystic Fibrosis Foundation, Northern Ohio Chapter

The Northern Ohio Chapter of the Cystic Fibrosis Foundation works to help develop a means to control and cure cystic fibrosis and to improve the lives of those with the disease. The chapter serves 28 counties throughout Northern Ohio.

Cystic Fibrosis Trust

•        Cystic fibrosis is chronically misunderstood, kills thousands worldwide and is carried unknowingly in the genes of millions. It's often invisible to the naked eye yet destroys lives, stopping them short, inflicting hardship and distress on patients, their families and carers. Cystic fibrosis directly affects around 10,000 people in the UK. &b...


New Lung Associates

New Lung Associates is a pulmonary group of physicians leading the Lung Transplant Program and the Adult Cystic Fibrosis Program at Tampa General Hospital, a 988-bed acute care hospital in Tampa, Fla. The New Lung Associates team has specialized focus in the care of advanced lung diseases, cystic fibrosis, and lung transplantation. New Lung Associatesâ€...

Talee Bio, Inc.

Talee Bio is a development stage biopharmaceutical company focused on developing gene therapy products for the treatment of cystic fibrosis. The company is developing two inhaled gene therapy drug candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentivirus gene therapy. The company was founded by...

Relevant

BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operat...

The Cystic Fibrosis Foundation

PathoGenesis Corporation

PathoGenesis Corporation develops and markets novel drugs to treat serious, chronic human infectious diseases where there is a significant need for improved therapy. In December 1997, the U. S. Food and Drug Administration approved ourfirst drug, TOBI (tobramycin solution for inhalation). TOBI is indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infec...

Scotland Online

Scotland Online has been one of Scotland's leading Internet services companies since it was founded in 1995. It has developed a first class reputation for delivering and managing, high-profile, business-critical applications and supporting infrastructures for a wide range of Scotland's public and private sector organisations.

Controlled Therapeutics (Scotland) Ltd

Controlled Therapeutics was founded in 1987 as a limited liability company organised under the laws of Scotland, and located at Peel Park Campus, 1 Redwood Place, East Kilbride, G74 5PB, Scotland. The company’s objective has always been to develop, manufacture and license pharmaceutical products based on patented drug delivery technologies

GCP Scotland

After 12 years experience in over 150 clinical trials with AstraZeneca, Hilary Birrell has set up a new Clinical Research Consultancy Company. Based in Dunfermline, Fife, GCP Scotland is aimed at the Pharmaceutical and Biotechnology industry in Scotland.Hilary’s experience and training (firstly as a study manager and then as a GCP manager) provide the basis for this new company, which offers the...

Coalition for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thir...

The Royal Society of Edinburgh

The Royal Society of Edinburgh (RSE) is an educational charity, registered in Scotland. Independent and non-party-political, we are working to provide public benefit throughout Scotland and by means of a growing international programme. The RSE has a peer-elected, multidisciplinary Fellowship of 1400 men and women who are experts within their fields.The RSE was created in 1783 by Royal Charter for...

PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and...

SciClone Pharmaceuticals

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cancer, immune system disorders and cystic fibrosis.

Cystic Fibrosis Enters the Proteomics Scene

As a continuation to genomic research, proteomics now offers the unique advantage to examine global alterations in the protein expression patterns of CF cells and tissues. The systematic use of proteomics should ultimately result in the finding of new prognostic markers...

Axentis Pharma AG

Axentis Pharma is a Swiss-based pharmaceutical company focused on chronic lung diseases and respiratory related disorders, especially on cystic fibrosis. Axentis Pharma is solely financed by private investors. The company is currently looking for co-development and co-marketing partners in the respiratory arena with the goal to create a competence center for healthcare professionals and patients...

ZappRx, Inc.

ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payer...

Pharmaxis Ltd

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes: Bronchitol for cystic fibrosis, b...

ZappRx

ZappRx simplifies the complex process required to order specialty medications, making it easier to collect and save all of the information required to order a prescription — including pharmacy information, payer/prior authorization requirements, and relevant patient clinical history. ZappRx then enables providers, pharmacists, and payers to digitally ...

PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Boomer Esiason Foundation and Adorama

BEF supports the cystic fibrosis community through scholarships, transplant grants, exercise programs, and educational programs as well as funding CF research. To date, BEF has raised over $130 million. Please visit Esiason.org to learn more about our programs, teamboomer.org to join the team, and follow us at facebook.com/BoomerEsiasonFoundation an...

Corus Pharma Inc

Corus Pharma seeks to develop drugs to treat unmet needs in the infectious diseases and respiratory areas. The company's core competencies reside in the identification of drug candidates, rapid clinical development and FDA approval of its products. Target development candidates will be identified through a combination of internal ideas, academic research and a search of projects in other organizat...

AmpliPhi BioSciences Corporation

AmpliPhi Biosciences Corporation (AmpliPhi) is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform. Our lead product development programs target Gram negative bacterial infections that are often resistant to existing antibiotic treatments. They include BioPhage-PA f...

Aradigm Corporation

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of cystic fibrosis, bronchiectasis, inhaled bioterrorism infections and smoki...


More From BioPortfolio on "Scotland provide year cystic fibrosis drug"

Quick Search

Corporate Database Quicklinks